Body Pharm Retatrutide 64 Pen

The Body Pharm Retatrutide 64 Pen is a prefilled research peptide device containing 64mg of retatrutide total, diallable up to 8mg per weekly injection following a 2mg → 4mg → 8mg → 8–12mg titration pattern.

Retatrutide is a GIP/GLP-1/glucagon triple-agonist that produced a mean 24.2% body-weight reduction at 48 weeks in the 2023 Phase 2 NEJM trial. The 64mg pen is the highest-volume Body Pharm format, delivering roughly double the supply duration of the 32mg pen — a more cost-efficient choice for protocols running 10 weeks or longer.

Research use only. Retatrutide is not registered with SAHPRA, FDA or EMA as of mid-2026 and remains investigational. Supplied for laboratory research purposes.

Key Takeaways

• The 64mg pen holds more peptide per rand than the 32mg format
• Phase 2 data shows a mean 24.2% body-weight reduction at 12mg weekly over 48 weeks, with no plateau by study end due to glucagon-driven hepatic lipolysis
• Retatrutide has no SAHPRA, FDA or EMA approval as of mid-2026 and remains investigational under Phase 3 TRIUMPH (NCT05929066)
• The pen requires 2–8 °C refrigeration with no freeze-thaw cycles; JCSG.org ships with full cold-chain integrity
• A single 64mg pen is one SKU and one lot number, removing mid-study re-order risk

What is the Body Pharm Retatrutide 64 Pen?

The Body Pharm Retatrutide 64 Pen is a pre-filled research peptide injector containing 64mg of retatrutide total. It carries the Body Pharm label and is sold through JCSG.org in South Africa as a research chemical, not a registered medicine [1]. That classification matters: retatrutide has no SAHPRA, FDA or EMA approval as of mid-2026, and the SA supply channel is positioned for laboratory research use only because the compound remains investigational [1].

The device is a multi-dose pen with an on-pen dial running up to an 8mg marker, so the operator can draw up to 8mg per weekly administration in line with the 2mg → 4mg → 8mg → 8–12mg titration pattern [1].

Mechanistically, retatrutide is a triple agonist at the GIP, GLP-1 and glucagon receptors. That sets it apart from dual-agonist comparators because it activates three distinct metabolic pathways rather than two. Readers wanting the underlying pharmacology should consult the retatrutide overview page for receptor-binding and Phase 2 efficacy context, or the tirzepatide page for a side-by-side with the dual GLP-1/GIP class.

Retatrutide's Triple-Agonist Mechanism Explained

Retatrutide (LY3437943) is a single-molecule triple agonist that hits the GLP-1, GIP and glucagon receptors simultaneously. Eli Lilly developed it, and the third receptor target distinguishes it from every other incretin-class peptide currently in clinical development [2]. That combined receptor profile is the pharmacological reason the 12mg weekly dose produced a mean 24.2% body-weight reduction over 48 weeks in the Jastreboff et al. Phase 2 obesity trial published in the New England Journal of Medicine in 2023 — the largest single-agent reduction reported at that time [2].

How retatrutide differs from semaglutide and tirzepatide

Semaglutide is a mono-agonist. It binds the GLP-1 receptor only, driving satiety and slowed gastric emptying with no direct action at GIP or glucagon sites. Tirzepatide adds one receptor: it activates GLP-1 and GIP, layering on an insulinotropic and adipocyte-signalling effect absent from semaglutide. The receptor-binding contrast is laid out on the tirzepatide page. Retatrutide goes a step further by adding glucagon receptor co-agonism on top of GLP-1 and GIP activity.

Why the glucagon receptor matters

Glucagon receptor activation drives hepatic energy expenditure and lipolysis. That is the mechanistic basis researchers cite for retatrutide's weight-loss curves not plateauing at 48 weeks in the Phase 2 dataset — unlike the flattening typically seen with GLP-1 mono-agonists, because the liver continues to mobilise fat stores [2]. The trade-off: glucagon activity can transiently raise fasting glucose and heart rate, so the net glycaemic effect depends on GLP-1's insulinotropic dominance offsetting glucagon's hepatic output. The Body Pharm 64 pen titration ladder (2mg → 4mg → 8mg → 8–12mg) mirrors the Phase 2 escalation schedule used to manage that tolerability profile [1][2].

Current development status

Retatrutide is still investigational as of mid-2026. The Phase 3 TRIUMPH programme (NCT05929066) is ongoing, and no peer-reviewed interim Phase 3 efficacy data has been published to supersede the 2023 NEJM Phase 2 paper [1][2]. Researchers wanting deeper receptor-binding context can consult the retatrutide overview before finalising a comparison protocol.

Phase 2 Clinical Evidence: What the Data Shows

The strongest published efficacy signal for retatrutide is a mean 24.2% body-weight reduction at 48 weeks in the 12mg arm of the 2023 NEJM Phase 2 obesity trial by Jastreboff et al. [2]. No peer-reviewed Phase 3 dataset has superseded it as of mid-2026 [1][2]. Researchers should note that Phase 2 data describes clinical-trial pharmacology in supervised participants, not the research-chemical sourcing context in which the Body Pharm pens are sold.

Trial design and dose arms

The Phase 2 trial randomised adults with obesity (BMI ≥30, or ≥27 with a weight-related complication) across placebo and four retatrutide dose ceilings: 1mg, 4mg, 8mg and 12mg, given subcutaneously once weekly with stepped titration. The primary endpoint was percentage change in body weight at 24 weeks, with a secondary endpoint at 48 weeks [2]. The 8mg and 12mg arms produced 22.8% and 24.2% reductions respectively. The curve had not flattened by week 48 because the triple-agonist profile continued to drive hepatic lipolysis [2]. That observation is what keeps interest alive in the triple-agonist profile relative to GLP-1 mono-agonists and the GLP-1/GIP dual agonism covered on the tirzepatide page.

Safety signals worth flagging

Jastreboff et al. reported dose-dependent gastrointestinal adverse events — nausea, diarrhoea, vomiting, constipation — as the dominant tolerability issue, alongside transient heart-rate increases that attenuated over time [2]. No unexpected safety signals surfaced at the doses tested. The trial was not powered or sized to detect rare events, and any research protocol design should account for that gap.

Phase 3 status and verification steps

The Phase 3 TRIUMPH programme (NCT05929066) is ongoing as of mid-2026, and no Phase 3 efficacy or safety publication has appeared to supersede the 2023 paper in the sources reviewed here [1][2]. Retatrutide has not received FDA, EMA or SAHPRA approval by mid-2026 [1][2]. Before finalising a comparison protocol, verify the current TRIUMPH status directly on ClinicalTrials.gov and cross-check PubMed for any post-2023 peer-reviewed safety or pharmacokinetic publications. The retatrutide overview is the starting point for mechanism context, but registry data should drive any claim about current trial readouts.

32mg vs 64mg Pen: Which Format Should You Order?

The 64mg pen delivers roughly double the supply duration of the 32mg format at a lower price-per-mg — making it the more cost-efficient choice for protocols running beyond five weeks. The fixed overhead of ordering and cold-chain shipping spreads across twice the peptide content. The 32mg pen suits shorter pilot work or first-time comparator runs. Both pens dial off the same on-pen 8mg marker as the maximum single weekly dose [1]. Researchers concerned about lot-to-lot consistency should note that a single 64mg SKU eliminates mid-study re-order risk.

Head-to-head specification table

Specification	32mg pen	64mg pen
Total peptide content	32 mg	64 mg
Maximum single weekly dose (on-pen marker)	8 mg	8 mg
Doses at 8 mg weekly	4	8
Supply duration at 8 mg weekly	~5 weeks (allowing titration)	~10 weeks (allowing titration)
Titration pattern (label)	2 → 4 → 8 mg	2 → 4 → 8 → 8–12 mg
Price per mg	See buy box	See buy box
Mid-study re-order risk	Higher (shorter supply)	Eliminated (full protocol in one SKU)

Which format fits which protocol

For a 10–12 week comparator study, or any protocol running the full titration arc (2 → 4 → 8 → 8–12 mg), the 64mg pen is the clear buy. One SKU and one lot number eliminate mid-study re-order risk, and the lower price-per-mg compounds savings across the full protocol duration [1]. For a short tolerability pilot, a 4–5 week dose-finding window, or a first procurement where lot-to-lot consistency is still being assessed, the 32mg pen is the lower-commitment entry point.

Either format sits in the same regulatory position: investigational, unregistered with SAHPRA, and mechanistically distinct from the dual GLP-1/GIP agonism profiled on the tirzepatide page. Pen format changes cost efficiency and protocol fit — not pharmacology.

Pen Operation and Storage for Research Use

The Body Pharm 64mg pen ships pre-filled, so no reconstitution with bacteriostatic water is required before dosing [1]. That is the operational difference researchers should weigh against lyophilised vial formats: vials demand sterile reconstitution, accurate diluent measurement, and a stability clock that starts the moment water meets powder. The pen arrives ready to dial and inject. For longitudinal protocols running across 10–12 weeks, removing the weekly reconstitution step cuts handling variance between doses and reduces contamination risk from repeated vial punctures.

Dialling the dose

The 64mg pen is dialled in whole-milligram increments using the on-pen marker, with retailer documentation referencing an 8mg maximum single weekly dose to support the published 2 → 4 → 8 → 8–12 mg titration arc [1]. The exact total injection count at each titration step should be confirmed against the insert supplied with the pen.

Storage and stability

Standard peptide-handling practice for GLP-class agonists in aqueous pen format is refrigeration at 2–8 °C, no freezing, and protection from direct light and UV. Freeze-thaw cycles denature the peptide backbone; prolonged ambient excursions shorten the usable in-use window. Both are the most common avoidable causes of activity loss in injectable peptide formulations. Verify the carton insert before commencing a protocol. JCSG.org ships the Body Pharm 64 Pen with full cold-chain integrity to South African addresses.

For mechanistic background, the retatrutide overview covers the triple-agonist pharmacology in depth, and the tirzepatide page provides the dual GLP-1/GIP comparator most researchers benchmark against when designing handling protocols.

Ordering the Body Pharm Retatrutide 64 Pen in South Africa

JCSG.org supplies the Body Pharm Retatrutide 64 Pen in South Africa. The current ZAR price is shown in the buy box at the top of this page.

Ordering details:

• ZAR pricing shown in the buy box
• Cold-chain shipping at 2–8 °C from order to delivery
• Full Body Pharm product range, including the 32mg pen for shorter protocols
• Batch number and expiry confirmed on every order

What to confirm before your order ships

• Carton insert with batch number and expiry is supplied
• Cold-chain shipping (2–8 °C) is confirmed end-to-end — JCSG.org maintains this by default
• The pen is the 64mg total-content format, not a relabelled 32mg unit
• The product is the current Body Pharm SKU, not older stock approaching expiry

For mechanistic context when evaluating the product, the retatrutide overview and the tirzepatide comparator page set the pharmacological baseline.

Regulatory Status

Retatrutide is not registered with SAHPRA as a medicine for human use as of mid-2026 [1]. It is marketed in South Africa through the research peptide channel, not as a scheduled, registered therapeutic. Verify current SAHPRA listing status independently before any procurement decision.

Internationally, retatrutide (Eli Lilly development code LY3437943) has not received FDA or EMA marketing authorisation for any indication as of mid-2026 [1]. It remains investigational under the Phase 3 TRIUMPH programme (ClinicalTrials.gov NCT05929066), with no peer-reviewed Phase 3 efficacy or safety dataset superseding the 2023 Phase 2 NEJM obesity paper by Jastreboff et al. at time of writing [1][2].

Legislative framework and researcher obligations

The Medicines and Related Substances Act (Act 101 of 1965, as amended) governs the manufacture, sale and possession of medicines and scheduled substances in South Africa. Institutional researchers should route procurement through their ethics committee and obtain independent legal review. This page is not legal advice.

Research use only. Supplied for laboratory research purposes only. Not for human consumption. Verify SAHPRA scheduling status before purchase.

Mechanistic background sits on the retatrutide overview page, with the tirzepatide comparator covering the registered dual-agonist benchmark.

Related Peptides and Further Research Resources

Researchers comparing retatrutide against adjacent incretin and metabolic compounds can route through the site's broader peptide index for mechanistic context. The retatrutide overview page consolidates the triple-agonist pharmacology (GLP-1, GIP, glucagon) and links the 32mg and 64mg pen formats discussed here.

For comparator work, the tirzepatide page covers the registered dual GLP-1/GIP agonist benchmark. Semaglutide sits a step further back as the GLP-1 mono-agonist baseline. Adjacent metabolic peptide research areas worth scoping include MOTS-C, AOD-9604, and CagriSema.

Browse all Body Pharm peptides.

Primary external references remain the Jastreboff et al. 2023 Phase 2 obesity trial in the New England Journal of Medicine and the ongoing TRIUMPH Phase 3 programme registered as NCT05929066 on ClinicalTrials.gov [1][2].

---

Sources

[1] Body Pharm Retatrutide 64 Pen product documentation (retailer label, JCSG.org listing) [2] Jastreboff AM et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine 2023; 389:514–526. DOI: 10.1056/NEJMoa2301972